

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/105809 A1

- (51) **International Patent Classification⁷:** A61K 9/20
- (21) **International Application Number:** PCT/IN02/00207
- (22) **International Filing Date:** 14 October 2002 (14.10.2002)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
533/MUM/2002 17 June 2002 (17.06.2002) IN
- (71) **Applicant (for all designated States except US):** THEMIS LABORATORIES PRIVATE LIMITED [IN/IN]; Unit No. S-4 Khira Industrial Estate, B.M. Bhargava Road, Santacruz (West), Mumbai 400 054, Maharashtra (IN).
- (72) **Inventors; and**
(75) **Inventors/Applicants (for US only):** ANTARKAR, Amit, Krishna [IN/IN]; House No. C/4, Rani Laxmi Nagar, Nagpur 440 022, Maharashtra (IN). LALA, Rajendra, Ghanshamlal [IN/IN]; House No. 100, "Guru Cottage", Inlaks Hospital Road, Chembur, Mumbai 400 074, Maharashtra (IN). KAMDAR, Nirav, Mahendra [IN/IN]; Dina Patil Estate, Block No. B-6, First Floor, Station Road, Bhandup (West), Mumbai 400 078 Maharashtra (IN). GADKARI, Parag, Narayan [IN/IN]; 23/703 Anant, Vasant Vihar, Pokhran Road No.2, Thane (West) 400 607, Maharashtra (IN). SHAH, Maya, Janak [IN/IN]; Saujanya, 3RD N.S Road, Vallabh Nagar Society, Vile Parle (West), Mumbai 400 056, Maharashtra (IN). SHAH, Janak, Ramanlal [IN/IN]; Saujanya, 3RD N.S Road, Vallabh Nagar Society, Vile Parle (West), Mumbai 400 056, Maharashtra (IN).
- (74) **Agent:** GANGULLI, Prabuddha; "Vision - IPR", 103B Senate, Lokhandwala Township, Akurli Road, Kandivali East, Mumbai 400 101, Maharashtra (IN).
- (81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,

[Continued on next page]

WO 03/105809 A1

(54) **Title:** MULTILAYER TABLETS CONTAINING THIAZOLIDINEDIONE AND BIGUANIDES AND METHODS FOR PRODUCING THEM

(57) **Abstract:** A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer layer comprises of a mixture of excipients and thiazolidinediones or thiazolidinediones and biguanide allowing immediate release of thiazolidinediones or thiazolidinediones and biguanide respectively and the other layer arranged in contact with the immediate release layer which comprises of a novel composition of excipients and a minimum one or more non-biodegradable, inert polymer(s) and the biguanide allowing pH independent prolonged release of the biguanide up to a period of 8-12 hours. The tablets are for once a day dosing. The tablets may optionally be film coated or enrobed by soft gelatin ribbons for additional protection against oxidation, photodegradation, identification, ease of swallowing, taste masking and for aesthetic appeal without altering the dissolution profile.



TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, *ARIPO patent*
(GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

MULTILAYER TABLETS CONTAINING THIAZOLIDINEDIONE AND BIGUANIDES AND METHODS FOR PRODUCING THEM

Background of Invention:

Diabetes mellitus is a major health care problem not only in the developing countries but also in the developed countries. The main therapeutic goal in Type 2 Diabetes Mellitus (DM) is non-insulin dependent Diabetes Mellitus is to control hyperglycemia which is due to derangement of insulin resistance & impaired insulin secretion, altered lipemia, affected glucose metabolism and other factors & prevent hypoglycemia due to drug therapy.

It has now been proved that combination therapy with two or more antidiabetic agents belonging to different class often results in dramatic improvement in glycemic control, and a better control can be achieved through combination therapy compared to using a large dose of single active ingredient. A combination of antidiabetic agents results in additive or synergistic therapeutic effect, which can restore glucose control when one single agent alone is not successful. Accordingly, such combinations are useful in treating diabetes and associated complications.

Thiazolidinediones such as Pioglitazone HCl is a new class of compounds and are insulin sensitivity enhancers. The plasma elimination half-life ($t_{1/2}$) for Pioglitazone HCl at steady state concentrations is 3.3–4.9 hours. The metabolites of Pioglitazone HCl are active in-vivo. Hence, for total Pioglitazone HCl (parent drug and metabolites) the $t_{1/2}$ is 16 to 24 hours [Gillies PS & Dunn CJ. Drugs 2000; 60(2): 333-343].

Biguanide, in particular Metformin HCl, increases the sensitivity to insulin in peripheral tissues of the hosts. Metformin HCl is also involved in inhibition of glucose absorption from the intestine, suppression of hepatic gluconeogenesis, and inhibition of fatty acid oxidation. It has an absolute oral bioavailability of 40 to 60% and gastro-intestinal absorption is apparently complete within 6 hours of the ingestion. An inverse relation is observed between the dose ingested and the relative absorption with the therapeutic doses of ranging from 0.5 to 1.5gm, suggesting the involvement of active, saturable absorption process.

The plasma half-life of Metformin HCl is 1.5-4.9 hours [Bailey CJ et al. New Eng. Journal of Medicine 1996; 334: 574-579]. Suitable dosage regimens of Metformin HCl include unit doses of 500 mg two to three times daily and can even be built up to five times daily or 850 mg once or twice daily. [Martindale, The Complete Drug Reference. Sweetman SC (Ed) 33rd Ed 2002]

Metformin HCl and Pioglitazone HCl have differing mode of peripheral action, which leads to synergy of drug action and better control of diabetic state. Multiple dosing regimens together, along with large doses, dose dependent absorption, poor bioavailability of Metformin HCl are not preferred since it leads to patient non-compliance, potential side effects & danger of overdosing. It is therefore imperative to shift from multiple dosing to once-a-day or twice-a-day dosing regimens. Longer plasma elimination half-life of Pioglitazone HCl substantiates the recommendation of once daily dosing regimen of Pioglitazone HCl.

The need has therefore been to provide formulations and processes to deliver the active pharmaceutical ingredients ensuring prolonged release of Metformin HCl and instant release Pioglitazone HCl from the formulation when consumed.

Prior Art

US Patent Nos. 6,011,049, No.6150384, 5965584, and 5952356 recommended separate or co-administration of Metformin HCl and Pioglitazone HCl. However they do not teach the art of formulation or preparing a single integral unit containing a combination of the drugs or single integral unit where biguanide has prolonged release characteristics.

US Patent Nos. 6296874, 6403121, US Patent Applications 20010036478, 20010034374, and 20010046515 describe core formulation of either Troglitazone or Pioglitazone HCl microspheres covering Metformin HCl microspheres core to provide single integral unit. The treatment does not require the prolonged release of Pioglitazone HCl or Troglitazone, as the drug inherently has longer half-life. The patents also recommend tailoring the formulations as per the patient's need, which is difficult to manufacture on a mass scale. Moreover the manufacture of such formulations involves a number of cumbersome steps making it unattractive for industrial operations.

PCT Publication WO01/35940, describes the use of Thiazolidinedione derivatives especially one described in EP0306228 along with another anti-diabetic agent Metformin HCl as a single integral unit multilayer tablet. The thiazolidinedione is formulated on the surface of Metformin HCl tablet using a coating technique. The release of both the drugs is immediate. This art does not teach how to formulate prolonged release of Metformin HCl and immediate release of Pioglitazone HCl in a single dosage form.

PCT Publication WO01/35941 describes the use of Thiazolidinedione derivatives especially one described in EP0306228 along with another anti-diabetic agent Metformin HCl as a single integral unit tablet or multilayer tablet. The thiazolidinedione and suitable carrier are formulated with Metformin HCl and its carrier in a single tablet or they are compressed into multi layer tablet with intention to solve incompatibility observed between Polyvinyl pyrrolidone and Thiazolidinedione. This formulation and dosage form has a major shortcoming as the formulation and the tablet form demonstrates the simultaneous release of both the drugs. This is not a desirable feature.

PCT Publication No. WO00/28989 describes the use of Thiazolidinedione derivatives described in EP0306228 along with another anti-diabetic agent such as Metformin HCl as a single integral unit single layer or multilayer tablet. It claims to sustain or delay the release of thiazolidinedione alone or both the drugs. Sustained release or delayed release of thiazolidinedione is not desired due to the inherent long half-life of the drug. The publication does not teach the art of selectively prolonging the release of Metformin HCl with immediate release of Thiazolidinedione.

US Patent No.5955106 describes a process for the preparation of Metformin HCl 850mg retard tablet, containing hydrocolloid forming retarding agent and further coating it to have a retarding film envelope for controlling the release of drug. The process involves tableting of the Metformin core, to marginally retard its release with the major retardation in release resulting from the retarding film coat. The patent does not in any manner teach the manufacture of bi-layered compositions containing Metformin HCl and Pioglitazone HCl where it is desirable to prolong the release of Metformin HCl.

PCT Publication No. WO9947128 describes the preparation of Metformin HCl controlled release tablet using biphasic delivery where Metformin HCl is blended with a hydrophilic or hydrophobic polymer to form granules, which are further dispersed or embedded in one or more hydrophilic or hydrophobic polymer or material. However if these biphasic granules are to be used for the preparation of bilayered tablets of Metformin HCl and sulfonyl urea or thiazolidinedione, the size of the tablet becomes relatively large causing inconvenience in swallowing.

Marketed antidiabetic combination preparation is Glucovance RTM, of Bristol Myers Squibb (Physician Desk Reference, Ed.55, Pg. 3477), which comprises of Metformin HCl and Glyburide as a single integral unit immediate release tablet.

Thus there is no prior art that teaches patient-convenient cost effective pharmaceutical compositions and the manufacture of granules containing biguanide capable of being compressed into tablets with pH independent prolonged release of the biguanide. Further the prior art does not teach compositions and manufacture of granules containing biguanide capable of being compressed into bilayered tablets with the other layer comprising of active pharmaceutical ingredients belonging to class of thiazolidinedione, sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers for desired layer-selective immediate release of these active pharmaceutical ingredients and pH independent, prolonged in-vitro release of biguanide. The prior art also does not teach compositions and methods of manufacturing of multiplayer tablets with such characteristics.

Objects of the invention:

The object of the invention is to provide process for the manufacture of patient convenient, cost effective antihyperglycemic pharmaceutical compositions in multi-layered tablet dosage form capable of layer-selective prolonged release of one active pharmaceutical ingredient(s) in the group of biguanides and layer-selective of immediate release of another active pharmaceutical ingredients belonging to the group of thiazolidinediones, sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers.

Another object of the invention is to provide process for the manufacture of patient convenient, cost effective antihyperglycemic pharmaceutical compositions in bilayered tablet dosage form capable of layer-selective prolonged release of one active pharmaceutical ingredient(s) in the group of biguanides and layer-selective of immediate release of active pharmaceutical ingredient(s) belonging to the group of thiazolidinediones.

It is another object of the invention to provide novel composition of granules containing biguanides that are capable of being effectively compressed into a single tablet system exhibiting pH independent prolonged release of biguanide.

It is yet another object of the invention to provide novel composition of granules containing biguanides that are capable of being effectively compressed into a multilayered tablet system for desired layer-selective prolonged and immediate release of the active pharmaceutical ingredients.

It is further an object of the invention to provide prolonged release granules containing Metformin HCl which are suitable for preparation of multi-layered/bi-layered tablets with layer selective drug release characteristics that are stable on prolonged storage without altering the granule characteristics such as moisture content, flowability etc. and compression characteristic such as hardness, friability etc.

It is another object to provide a process for manufacturing pharmaceutical composition in a multi layered tablet form capable of layer- selective prolonged release of Metformin HCl and layer-selective immediate release of Pioglitazone HCl.

It is yet another object of the invention to provide process for the manufacture of bi-layered tablet of the antihyperglycemic pharmaceutical composition, wherein the layer containing Metformin HCl exhibits prolonged release and the layer containing Pioglitazone HCl exhibits immediate release profiles.

It is yet another object of the invention to provide process for the manufacture of a multi-layered/bi-layered tablet wherein the layer-selective drug release profiles are predictable and exhibit reproducible in-vivo performance without the problems of dose dumping and burst effect of the formulation.

It is further an object of the invention to provide process for the manufacture of multi-layered tablets described herein, where the prolonged release of Metformin HCl layer is pH independent and the formulation processed for once a day dosing.

It is further an object of the invention to release Pioglitazone HCl immediately from layers of the multi-layer tablet and made available for the absorption.

It is further an object of the invention to provide the above-mentioned multi-layered tablets of desired hardness, low friability without capping.

It is further an object of the invention to provide novel composition for the manufacture of "once a day" multi-layered tablets wherein the release of Metformin HCl is pH independent and prolonged whereas the release of Pioglitazone HCl is immediate such that the size of the tablet is convenient to swallow.

It is further an object of the invention to provide a formulation and dosage form to ensure bioavailability and minimal inter-patient variation in the pharmacokinetic parameters.

Summary of the invention:

Novel compositions of the present invention is processed to prepare granules for the manufacture of patient convenient, cost effective pharmaceutical compositions in multi-layered tablet dosage form capable of layer-selective prolonged release of one active pharmaceutical ingredient(s) in the group of biguanides and layer-selective of immediate release of active pharmaceutical ingredient(s) belonging to the group of thiazolidinediones, sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers.

Also novel compositions of the present invention is processed to prepare a multilayered tablet for example in the limiting case of a bilayered tablet with minimum two superimposed layers, characterized in that

- A layer containing novel composition of the active pharmaceutical ingredient(s) or their pharmaceutically acceptable salts belonging to the class Thiazolidinedione e.g.

- Pioglitazone HCl with or without Biguanide e.g. Metformin HCl and a mixture of desired excipients and
- Another layer, containing novel composition of the drugs or its pharmaceutically acceptable salt belonging to the class of Biguanide e.g. Metformin HCl, one or more polymers and desired excipients which is in contact with the first layer,

are manufactured using specially formulated and processed granules containing Metformin HCl capable of being compressed into a layer to allow the pH independent, in-vitro prolonged release of Metformin HCl up to a period of 8-12 hours from selective layer and processed granules containing thiazolidinedione e.g. Pioglitazone HCl for immediate release of thiazolidinediones from the other selective layer.

The bi-layered tablet features may be extended to provide process for the manufacture of antihyperglycemic pharmaceutical compositions in multi-layered tablet dosage form capable of layer-selective prolonged release of active pharmaceutical ingredient(s) in the group of biguanides and layer-selective immediate release active pharmaceutical ingredient(s) belonging to the group of thiazolidinediones.

The manufacturing process involves the separate preparation of specially formulated granules containing Metformin HCl and Pioglitazone HCl and then compressing them into multilayered tablets exhibiting prolonged pH independent in-vitro release of Metformin HCl upto a period of 8-12 hours and immediate release of Pioglitazone HCl.

The tablets so prepared show hardness of 6.0 - 12.0 Kgs / sq.cm, minimal friability and no capping.

The bilayered tablets may further be film coated for aesthetic appeal or enrobed into soft gelatin ribbons for ease of swallowing, additional protection against oxidation, photodegradation, identification, taste masking, and or for aesthetic appeal without altering the dissolution profile.

The invention provides a fixed dose pharmaceutical composition suitable for management of diabetes mellitus, especially Type 2 diabetes mellitus and conditions associated with Type 2 diabetes mellitus

Detailed Description of the invention:

Thus in accordance with this invention, in the limiting case of a multi-layered tablet as a bilayered tablet offers options where;

- a) Both the layers are parallel to each other i.e. the second layer has upper surface & lower surface, only one of those surface being in contact with the first layer the shape of the tablet being generally capsule shaped or of any shape provided the release profile of the drug is not changed.
- b) The second layer is either completely covered by the first layer or only partially covered by it.

The active pharmaceutical ingredient(s) of the composition can be selected from the group belonging to the class of Biguanide, thiazolidinediones, sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers and their pharmaceutically acceptable salts.

For the purposes of describing the invention active pharmaceutical ingredient(s) of the composition is selected from the group belonging to the class of Biguanide and Thiazolidinedione. Examples of the active pharmaceutical ingredients in the class of Biguanides include Phenformin, Buformin and Metformin and their pharmaceutically acceptable salts. Examples of active pharmaceutical ingredients in the class of Thiazolidinediones include Rosiglitazone, Troglitazone and Pioglitazone and their pharmaceutically acceptable salts.

For the purposes of describing the invention, Pioglitazone HCl and Metformin HCl are selected as the drug for the first layer (immediate release) and the second layer (prolonged release) respectively.

Alternatively, a part of Metformin HCl can also be added in the formulation of the immediate release layer, which is not more than 10% of the dose of Metformin HCl per tablet.

The dose of Metformin HCl per tablet is in the range of 250mg -2000mg and the dose of Pioglitazone HCl equivalent to Pioglitazone per tablet is in the range of 15 - 60 mg. and dosage regime is 1-4 tablets once a day.

The preferred strength for Metformin HCl per tablet in the bilayer formulation is 500mg and Pioglitazone per tablet is either 15mg or 30 mg. This invention is not limited to above mention fixed dose combination but will include other fixed dose combinations also.

Thus in accordance with one of the embodiments of this invention where both the layers are parallel to each other i.e. the second layer has upper surface & lower surface, only one of those surface being in contact with the first layer, the process comprises

- Formulation of the composition of the various layers that will finally be used to form the tablet.
- Preparing the specially formulated granules containing the drugs to be "prolonged released" or "immediate released" from the selective layers of the multi-layered tablet. The granulation may be done by the methods of "dry granulation" or "direct compression" or "wet granulation".
- Screening and sizing the prepared granules.
- Treating the screened and sized granules with lubricants.
- Appropriately compressing the granules to create the tablets having selective layers as desired.

A) Granules containing Biguanides such as Metformin HCl of invention are prepared in following manner:

1. Metformin HCl is pulverized to particle size of less than 100 microns or less.
2. Metformin HCl is then blended with non-biodegradable, inert polymer(s). Blending is carried out in mixers such as planetary mixers, octagonal blenders, V-blenders or rapid mixer granulators or fluid bed granulators.
3. This drug polymer(s) blend is then wet granulated using a solvent that may optionally contain polymer(s), binders and plasticizers. The granulation solvent may be water or hydroalcoholic solution. Granulation can be carried in granulator such rapid mixer granulator, fluid bed granulator, planetary mixer or any other mixer used for granulation.
4. The granulated mass is dried and then sized using comminuting mill such as Fitz mill or oscillating granulator or any other equipment suitable for purpose, with an appropriate mesh preferably around 1-mm mesh.

5. The granules are then mixed with Talc, magnesium stearate and colloidal silicon dioxide.
 6. The resultant lubricated granules containing Metformin HCl are ready for compression to form the selective prolonged release layer.
- B] Granules containing Thiazolidinedione salts such as Pioglitazone HCl are prepared by methods such as wet granulation or blended to prepare directly compressible blend or using dry granulation as follows:
1. Pioglitazone HCl used is of particle size less than 30 microns.
 2. Blending of Pioglitazone HCl with fillers, disintegrants, binders, lubricants and permitted colours carried out in planetary mixer, octagonal blender, double cone blender, rotary mixer granulator, drum mixer, ribbon blender, fluid bed processor or any other suitable mixer.
 3. The resultant lubricated granules of Pioglitazone HCl are ready for compression to form a layer releasing the drug immediately from the bi-layered tablet or a set of layers of the multi-layered tablet.

Other active pharmaceutical ingredients belonging to the class of sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers can also be granulated using method for preparation of granules containing Thiazolidinedione, which are ready for compression to form a layer releasing the active pharmaceutical ingredient(s) immediately from the bi-layered tablet or a set of layers of the multi-layered tablet.

- C] The granules containing Biguanide and Thiazolidinedione are loaded in different hoppers of a tablet compression machine and then compressed into capsule shaped, biconvex, multilayered tablets having a immediate release of Thiazolidinedione (Pioglitazone HCl) and in-vitro pH independent prolonged release of Biguanide (Metformin HCl) upto a period of about 8 to about 12 hours. The shape of tablet is not limited to capsule shape and can vary so long as the desired drug release profile remains unaffected.

In another embodiments of invention formulation containing active pharmaceutical ingredient(s) such as sulfonyl urea, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers may be used instead of Thiazolidinedione as per therapeutic dose.

The fillers are selected but not limited to Microcrystalline Cellulose, Lactose, Dibasic Calcium Phosphate. The disintegrants are selected but not limited to sodium starch glycolate, crosscarmellose sodium, crosspovidone, starch, pregelatinized starch, low substituted Hydroxypropylcellulose. The binders are selected but not limited to Hydroxypropylmethylcellulose, Polyvinylpyrrolidone, and Hydroxypropylcellulose. The lubricating agents or glidants or antiadherants are selected but not limited to talc, Colloidal silicon dioxide, stearic acid, magnesium stearates, and calcium stearates.

The invention is not limited to carrying out a wet granulation method for the formulation that finally forms a set of the layers (e.g. the second layer in a bi-layered tablet) and direct compression method for the formulation that finally forms the other set of layers (e.g. the first layer in a bi-layered tablet). The formulations in the present invention may alternatively be processed by a range of granulation techniques to prepare the granules for use in the preparation of the various layers in the tablet.

The layer from which the release of Metformin HCl is prolonged comprises of one or more inert, non-biodegradable polymer(s), which swells & erodes in aqueous media & subsequently, releases the drug in the surrounding environment. The polymer is selected but not limited to Hydroxypropylmethylcellulose alone or combination of Hydroxypropylmethylcellulose with Sodium Carboxymethylcellulose or combination of Hydroxypropylmethylcellulose with Hydroxypropylcellulose or combination of Hydroxypropylmethylcellulose with Hydroxyethylcellulose or combination of Hydroxypropylmethylcellulose with Sodium Alginate or combination of Hydroxypropylmethylcellulose with Xanthan Gum or combination of Hydroxypropylmethylcellulose with Guar gum or combination of Hydroxypropylmethylcellulose with Sodium Carboxymethylcellulose and Meth(acrylic) acid Copolymers or combination of Hydroxypropylmethylcellulose with Sodium Alginate and Meth(acrylic) acid copolymer.

The copolymers derived from (meth)acrylic acids comprise the copolymers of derivatives of methacrylic acid and the copolymers of derivatives of acrylic acid and of derivatives of methacrylic acid. According to a preferred embodiment of the invention, the non-biodegradable inert polymeric material is chosen from the groups consisting of ethyl acrylate and methyl methacrylate copolymers,

ethylammonium methacrylate and methyl acrylate copolymers, ethylammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and methyl methacrylate copolymers, ethylammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers, methacrylic acid and methyl methacrylate copolymers.

Among these polymers copolymers of methacrylic acid and ethyl acrylate the preferred molecular weight are >100,000 daltons.

The nominal viscosity at 20°C of a 2%w/w aqueous solution of Hydroxypropylmethylcellulose used is not less than 3000cP. The nominal viscosity of a 1%w/w aqueous solution of Sodium alginate at 20°C is not less than 50cP. The nominal viscosity of a 1%w/w aqueous dispersion of Guar gum is not less than 2000 cP.

The nominal viscosity at 25°C of a 1%w/w aqueous solution of

- Hydroxypropylcellulose is not less than 1500cP.
- Hydroxyethylcellulose is not less than 1500cP.
- Sodium Carboxymethylcellulose is not less than 1500 cP.
- Xanthan gum is not less than 1200 cP

The formulation for the layer containing the Biguanide say Metformin HCl contains at least 35% of a polymer or a combination of the polymers and preferably between 40 - 65 % by weight of the Biguanide say Metformin HCl. The polymer combinations may vary as follows: in case of combination of two polymers, the polymers are used in the ratio of 1 : 0.01 - 1 : 3.5 and in case of combination of three polymers, the polymers are used in the ratio of 1 : 0.01: 0.1 - 1 : 3.5 : 0.5 depending on the polymers used.

The addition sequence of the polymer(s) is designed to achieve the desired final characteristics of the end product.

In the case of a bi-layered tablet, prolonged release layer comprises of drug Metformin HCl which is about 50% to about 80% by weight of the layer and immediate release layer comprises drug Pioglitazone HCl in the range of 5-50% of this layer.

The respective weight ratio of first layer and the second layer are not critical to the process of the invention and are adjusted according to the desired dosage.

The bilayered tablet which is formulated may be further enrobed into soft gelatin ribbons for ease of swallowing & / or for additional protection against photodegradation & oxidation & / or for taste masking and / or identification and / or for aesthetic appeal without altering the dissolution profile.

Examples

The invention is now illustrated with non-limiting examples for the preparation of bilayered tablets.

Example 1

The formulation for the preparation of the Metformin HCl prolonged release layer is as follows:

Metformin HCl	60.0%
Hydroxypropylmethylcellulose K4M	37.0%
Polyvinylpyrrolidone K30	0.75%
Talc	0.50%
Colloidal Silicon Dioxide	1.50%
Magnesium stearate	0.25%
Isopropyl Alcohol	qs
Purified Water	qs

Pulverized Metformin HCl and Hydroxypropylmethylcellulose are introduced in a mixer granulator and mixing is carried out for 10 minutes. Polyvinylpyrrolidone K30 is dissolved in granulating solvent (Isopropyl alcohol and water in the ratio of 80:20). This solution is then added or sprayed on to the resultant mixture into the mixer granulator to form granules. The granules are then dried in hot air oven or fluid bed drier to moisture content between 0.5-3.5%. The dried granules are then sized using multi-mill to a desired size (1.5 mm or less) and the sized granules are lubricated with Talc, Colloidal

Silicon Dioxide and Magnesium stearate and the resultant lubricated granules containing Metformin HCl are ready for compression to form a prolonged release layer.

The formulation for the preparation of selective layer showing immediate release is as follows:

Pioglitazone HCl	20.05% w/w
Microcrystalline Cellulose	24% w/w
Sodium Starch glycollate	10% w/w
L- HPC(LH 21)	9.0% w/w
Lactose	28.6 w/w
Hydroxypropylmethylcellulose	1.2% w/w
Talc	1.8% w/w
Colloidal Silicon Dioxide	3.65% w/w
Magnesium stearate	0.5 % w/w
Approved Lake colorant	1.2 % w/w

Pioglitazone HCl is blended with microcrystalline cellulose, Sodium starch glycollate, L-hydroxypropylcellulose (L-HPC [LH-21]), lactose and hydroxypropylmethylcellulose in a suitable mixer. Mixing is carried out for 10 minutes. Optionally the blend may be compacted and sized. Colorant, colloidal silicon dioxide, talc and magnesium stearate is then introduced in the mixer and mixing is carried for 10 minutes. The resultant lubricated granules containing Pioglitazone HCl are ready for compression to form a first layer.

The said granules containing Metformin HCl and Pioglitazone HCl are loaded in two different hopper of a tablet compression machine and then compressed into capsule shaped, biconvex, bilayered tablets.

Example 2

Another example for the preparation of the Metformin HCl Prolonged release layer is as follows

Metformin HCl	60.0%w/w
Hydroxypropylmethylcellulose	29% w/w
Xanthan Gum	9.25 w/w
Polyvinylpyrrolidone k30	0.25w/w
Talc	0.5w/w
Colloidal Silicon Dioxide	0.75w/w
Magnesium stearate	0.25w/w
Isopropyl Alcohol	qs
Purified Water	qs

Example 3

Another example for the preparation of the Metformin HCl Prolonged release layer is as follows

Metformin HCl	60.0%w/w
Hydroxypropylmethylcellulose	9.0%w/w
Sodium Carboxymethylcellulose	25.4%w/w
Methacrylic acid copolymer dispersion	3.5%w/w
Polyethylene Glycol 6000	0.35%w/w
Polyvinylpyrrolidone k30	0.25%w/w
Talc	0.5%w/w
Colloidal Silicon Dioxide	0.75%w/w
Magnesium stearate	0.25%w/w
Purified water	qs

Metformin HCl, Hydroxypropylmethylcellulose, Sodium carboxymethylcellulose are mixed and further granulated with methacrylic acid copolymer dispersion containing binder and plasticizer.

Alternatively, granules containing Pioglitazone HCl as a selective immediate release layer can also be prepared by wet granulation method, the example for which is given below.

Pioglitazone HCl	20.05% w/w
Microcrystalline Cellulose	30.3% w/w
Sodium Starch glycollate	10% w/w
Lactose	34.5 w/w
Hydroxypropylmethylcellulose	1.2% w/w
Talc	1.0% w/w
Colloidal Silicon Dioxide	1.25% w/w
Magnesium stearate	0.5 % w/w
Approved Lake colorant	1.2 % w/w
Purified water	qs

Pioglitazone HCl is blended with microcrystalline cellulose, Sodium Starch glycollate and Lactose in a suitable mixer granulator. Mixing is carried out for 10 minutes.

The mix is then granulated with hydroxypropylmethylcellulose solution in water. The granules are then dried to moisture content between 0.5-2.50%.

In other embodiments of invention formulation containing active pharmaceutical ingredient(s) such as sulfonyl urea, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers may be used instead of Thiazolidinedione as per therapeutic dose.

The dried granules are then sized using multimill to a desired size (1.5mm or less) and the sized granules are lubricated with colorant, talc, colloidal silicon dioxide and magnesium stearate and the resultant lubricated granules containing Pioglitazone HCl are ready for compression.

Dissolution and in-vitro Drug Release Profile

The tablets are analyzed using USP Dissolution Apparatus II. The Dissolution Media for Metformin HCl is either Distilled Water or 0.1N HCl or pH 6.8 Phosphate Buffer, Media Volume 900ml. The release specification is given below.

Time Interval (Hours)	Range of % Drug Released
1	25-45
4	50-80
8	Not less than 75%

The Dissolution Media for Pioglitazone HCl is 0.1N HCl, Media Volume 900ml and its release specification is given below.

Time Interval (min)	Range of % Drug Released
30	Not less than 80

The in-vitro dissolution profile achieved with bilayer tablet formulation of above described example in 0.1N HCl or 6.8pH Phosphate buffer or Distilled water for Metformin HCl using dissolution apparatus USP Type II with 900ml media volume is as follows.

Time Interval (Hours)	Cumulative % Drug Released
1	28-38
4	65- 72
8	85- 95

The in-vitro dissolution profile achieved with bilayer tablet formulation of above described example in 0.1N HCl Pioglitazone HCl using dissolution apparatus USP Type II with 900ml media volume is as follows.

Time Interval (minutes)	% Drug Released
10	>85%

CLAIMS.

We claim:

1. A process for the manufacture of multi-layered tablet dosage of antihyperglycemic pharmaceutical compositions for once a day administration comprising
 - a) preparing the novel granules formulation containing the biguanide or its pharmaceutically acceptable salts which is to be "prolonged released"
 - b) preparing the novel granules formulation containing the active pharmaceutical ingredients (API) or their pharmaceutically acceptable salts to be 'immediate released';
 - c) screening and sizing the prepared granules ;
 - d) treating the screened and sized granules with lubricants ; and
 - e) compressing the granules to create the tablets containing the layers as desired.
2. The process as claimed in claim 1 wherein the group of biguanides used are Metformin, Buformin and Phenformin and their Pharmaceutical acceptable salts such as Metformin HCl.
3. The process as claimed in claim 1 wherein the APIs used in claim 1 belong to the group of thiazolidinediones, sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers.
4. A process for the manufacture of composition as claimed in claim 1 wherein layer-selective immediate release of thiazolidinediones where the said thiazolidinediones is but not limited to Pioglitazone, Rosiglitazone, Troglitazone and their pharmaceutically acceptable salts thereof such as Pioglitazone HCl and are present in amount from about 5% to about 30% by weight of the corresponding layer.
5. A process as claimed in claim 1 wherein
 - a. The biguanide e.g. Metformin HCl is pulverized to particle size of less than 100 microns or less and it comprises atleast 48% and preferably over 50% of the formulation composition.
 - b. Metformin HCl is blended with non-biodegradable, inert polymer, blending carried out in mixers such as planetary mixers, octagonal blenders, V-blenders or rapid mixer granulators or fluid bed granulators.

- c. the API-polymer blend is wet granulated using a solvent optionally containing binders and plasticizers, in the presence of a granulation solvent being water or hydroalcoholic solution.
 - d. The granulated mass is dried followed by sizing using comminuting mill such as Fitz mill or oscillating granulator or any other equipment suitable for the purpose, with an appropriate mesh preferably around 1-mm mesh.
 - e. the granules thus produced are mixed with Talc, magnesium stearate and colloidal silicon dioxide.
6. A process as claimed in claim 1 wherein :
 - The particle size of Pioglitazone HCl used is less than 30 microns.
 - the pioglitazone HCl is blended with fillers, disintegrants, binders, lubricants and permitted colours carried out in planetary mixer, octagonal blender, double cone blender, rotary mixer granulator, drum mixer, ribbon blender, fluid bed processor or any other suitable mixer.
7. A process as claimed in claim 5, wherein the non-biodegradable, inert polymers are selected from the group consisting of cellulose derivatives, (meth)acrylic acid co-polymers, Xanthan gum, Guar gum, Alginates and their acceptable salt thereof.
8. A process as claimed in claim 7, wherein the non-biodegradable, inert polymers are selected from a minimum of one or more cellulose derivative or combination of cellulose derivatives with (meth)acrylic acid co-polymers or combination of cellulose derivatives with alginates and /or (meth)acrylic acid co-polymers or combination of cellulose derivatives with Xanthan gum or combination of cellulose derivatives with guar gum.
9. A process as claimed in claim 7- 8, wherein the cellulose derivative is alkylcellulose and/or hydroxyalkylcellulose and/or carboxyalkylcellulose, the (meth)acrylic acid co-polymers are selected from esters of ethyl acrylate and methyl methacrylate, ethyl ammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and methyl methacrylate copolymers, ethyl ammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers methacrylic acid and methyl methacrylate copolymers , alginate and their acceptable sodium and calcium salt.

10. A process for the manufacture of the compositions as claimed in claims 1,5,7 - 9 wherein the cellulose derivatives are selected from methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylhydroxyethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose and calcium carboxymethylcellulose are incorporated in amount of at least 35% by weight of the biguanide more preferably 40-65 % by weight of the biguanide.
11. A process as claimed in claims 1, 5, 7 - 10 wherein the binary combinations of the polymers are selected from combinations of hydroxypropylmethylcellulose and hydroxypropylcellulose; hydroxypropylmethylcellulose and hydroxyethylcellulose; hydroxypropylmethylcellulose and sodium carboxymethylcellulose; hydroxypropylmethylcellulose and sodium alginate; hydroxypropylmethylcellulose and Xanthan gum ; hydroxypropylmethylcellulose and guar gum; in the ratios ranging from about 1 : 0.01 to about 1 : 3.5.
12. A process as claimed in claims 1, 5, 7 - 10 wherein a combination of three polymers hydroxypropylmethylcellulose, sodium carboxymethylcellulose and methacrylic acid copolymer is used in ratios of about 1 : 0.01: 0.1 to about 1 : 3.5 : 0.5 respectively.
13. A process as claimed in claims 1, 5, 7 - 12 wherein the polymers used is at least 35% by weight of the biguanide most preferably 40-65 % by weight of the biguanide.
14. A process as claimed in claims 1, 5, 7 - 13 for the preparation of the antihyperglycemic pharmaceutical compositions in multi-layered/bi-layered tablet wherein the nominal viscosity at 20°C of a 2% w/w aqueous solution of hydroxypropylmethylcellulose used is not less than 3000cP, the nominal viscosity of a 1%w/w aqueous solution of Sodium alginate at 20°C is not less than 50cP and the nominal viscosity of a 1%w/w aqueous dispersion of guar gum is not less than 2000 cP.
15. A process as claimed in claims 1, 5, 7 - 13, wherein for the preparation of the antihyperglycemic pharmaceutical compositions in multi-layered/bi-layered tablet wherein the nominal viscosity at 25°C of a 1% w/w aqueous solution of hydroxypropylcellulose is not less than 1500cP; hydroxyethylcellulose is not less

than 1500cP.; sodium carboxymethylcellulose is not less than 1500 cP and xanthan gum is not less than 1200 cP.

16. A process as claimed in claims 1, 4, 6 wherein the disintegrating agents are selected from the group comprising starch, sodium starch glycolate, crosscarmellose sodium, crosspovidone, pregelatinized starch, microcrystalline cellulose, hydroxypropylcellulose.
17. A process for the composition as claimed in claims 1-6, 16 wherein the immediate release layer containing a combination of thiazolidinediones and biguanides with the excipients and other formulation ingredients comprises about 5% to about 30% by weight of the thiazolidinediones and about 1 to about 10% of biguanides.
18. A process according to claims 1 - 6 where Metformin HCl is in the range of 500mg -2000mg and Pioglitazone HCl equivalent to Pioglitazone is in the range of 15 - 60 mg.
19. A process according to claims 1, 2, 5 wherein the granules of the biguanide prolonged release layer formed can be stored for prolonged period without change in compression characteristic.
20. A process according to claim 1-19 wherein, the bilayer tablet formed has hardness in the range of about 6 to about 12 kg/ Sq. cm, low friability of <1% without capping.
21. A process for the manufacture of composition as claimed in claims 1-20 wherein the layers of the tablet are parallel to each other.
22. A process for the manufacture of composition as claimed in claims 1-20 wherein one layer is only partially covered by the next layer.
23. A process according to claims 1- 22 wherein, the multilayer tablet is enrobed by soft gelatin ribbons for additional protection against oxidation, photodegradation, identification, ease of swallowing, taste masking and for aesthetic appeal without altering the dissolution profile.
24. A process for manufacture of granules containing biguanide as or its pharmaceutically acceptable salts claimed in claims1, 2, 5, 7 - 15, 18 - 19 capable of being compressed to a tablet dosage form with pH independent prolonged release of biguanide at the end of 1, 4, and 8 hours lies in the range of 25 - 45%, 50 - 80% and not less than 75% respectively.

25. A process for manufacture of granules containing active pharmaceutical ingredients (API) or their pharmaceutically acceptable salts claimed in claims 1, 3 – 4, 6, 16, 18 capable of being compressed to a tablet dosage form with immediate release of the same is not less than 80 % at the end of 30 minutes.
26. A pharmaceutical compositions in multi-layered tablet dosage form capable of layer-selective prolonged release of one active pharmaceutical ingredient (API) or APIs in the group of biguanides and layer-selective of immediate release of another API or APIs belonging to the group of thiazolidinediones, sulfonyl ureas, alpha - glucosidase inhibitor, aldose reductase inhibitor, statins compound, squalene synthesis inhibitor, fibrates, angiotensin converting enzymes inhibitor, LDL catabolism enhancers.
27. A pharmaceutical composition claimed in claim 26 in which the prolonged release pharmaceutical ingredient belongs to the group of biguanides and the intermediate release active pharmaceutical ingredient belongs to the group of thiazolidinediones and/or biguanides.
28. A composition as claimed in claim 26-27 wherein the immediate release API or APIs are present in an amount of from 5%-30% by wt..
29. A composition as claimed in claims 26-28 wherein the immediate release layer containing a combination of thiazolidinediones and biguanides with the excipients and other formulation ingredients comprises about 5% to about 30% by weight of the thiazolidinediones and about 1 to about 10% of biguanides.
30. A composition as claimed in claims 26-29 capable of layer-selective prolonged release of biguanides where the said biguanides is but not limited to Metformin, Buformin and Phenformin and their Pharmaceutical acceptable salts such as Metformin HCl.
31. A composition as claimed in any one of claims 26-30 wherein layer-selective immediate release of thiazolidinediones where the said thiazolidinediones is but not limited to Pioglitazone, Rosiglitazone, Troglitazone and their pharmaceutically acceptable salts thereof such as Pioglitazone HCl.
32. A composition as claimed in claims 26-31, wherein the prolonged release layer contain Metformin HCl and the immediate release layer contain Pioglitazone HCl.

INTERNATIONAL SEARCH REPORT

 Informatic Application No
 PCT/in 02/00207

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 35941 A (LILLIOTT NICOLA JAYNE ;MACKENZIE DONALD COLIN (GB); SMITHKLINE BEE) 25 May 2001 (2001-05-25) page 2, line 8 - page 3, line 39 page 4, line 15 - line 26 examples 2,5-9,25 ---	1-4, 7-10,13, 16-18, 21,25-31
A	US 6 403 121 B1 (ADJEI AKWETE L ET AL) 11 June 2002 (2002-06-11) column 1, line 1 - line 43 ---	1-32
A	WO 00 28989 A (LILLIOTT NICOLA JAYNE ;LEWIS KAREN (GB); RE VINCENZO (GB); MACKENZ) 25 May 2000 (2000-05-25) page 1, line 1 - line 15 examples --- -/-	1-32

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

16 April 2003

Date of mailing of the international search report

08/05/2003

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-2016

Authorized officer

Rankin, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN 02/00207

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indicator, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 01 35940 A (LEWIS KAREN ;LILLOTT NICOLA JAYNE (GB)); MACKENZIE DONALD COLIN (GB) 25 May 2001 (2001-05-25) page 1, line 30 -page 2, line 2 examples -----</p>	1-32

INTERNATIONAL SEARCH REPORT

 International application No
 PCT/IN 02/00207

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0135941	A	25-05-2001	AU 1404001 A BG 106747 A BR 0015605 A EP 1231918 A2 WO 0135941 A2 NO 20022334 A SK 6792002 A3	30-05-2001 31-01-2003 09-07-2002 21-08-2002 25-05-2001 09-07-2002 10-09-2002
US 6403121	B1	11-06-2002	AU 2753501 A WO 0182875 A2 US 2001046515 A1	12-11-2001 08-11-2001 29-11-2001
WO 0028989	A	25-05-2000	AU 3033800 A BG 105568 A BR 9915285 A CA 2351058 A1 CN 1348369 T CZ 20011629 A3 WO 0028989 A1 EP 1131070 A1 HR 20010343 A1 HU 0104303 A2 JP 2002529504 T NO 20012303 A PL 347634 A1 SK 6442001 A3 TR 200101333 T2 ZA 200103843 A	05-06-2000 31-01-2002 07-08-2001 25-05-2000 08-05-2002 12-12-2001 25-05-2000 12-09-2001 30-06-2002 28-03-2002 10-09-2002 04-07-2001 22-04-2002 03-12-2001 22-10-2001 14-05-2002
WO 0135940	A	25-05-2001	AU 1403501 A EP 1231917 A2 WO 0135940 A2	30-05-2001 21-08-2002 25-05-2001